Randomized Controlled Trial of Molnupiravir SARS-CoV-2 Viral and Antibody Response in At-Risk Adult Outpatients

Non-hospitalized participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir or Usual Care were recruited to study viral and antibody dynamics and the effect of molnupiravir on viral whole genome sequence from 1437 viral genomes.